| You are here: Home: BCU 5|2002: Editor's Note - Select Publications
Select publications
Sir Richard Peto and the Early Breast Cancer
Trialists’ Collaborative Group
Collins R, Gray R, Godwin J, Peto R. Avoidance of large
biases and large random errors in the assessment of moderate treatment
effects: The need for systematic overviews. Stat Med 1987;6:245-
250. Abstract
Early Breast Cancer Trialists’ Collaborative Group. Effects
of adjuvant tamoxifen and of cytotoxic therapy on mortality in early
breast cancer: An overview of 61 randomized trials among 28,896
women. N Engl J Med 1988;319:1681-1691. Abstract
Early Breast Cancer Trialists’ Collaborative Group. Effects
of radiotherapy and surgery in early breast cancer: An overview
of the randomized trials. N Engl J Med 1995;333:1444-1455.
Abstract
Early Breast Cancer Trialists’ Collaborative Group. Ovarian
ablation in early breast cancer: Overview of the randomised trials.
Lancet 1996;348:1189-1196. Abstract
Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy
for early breast cancer: An overview of the randomised trials.
Lancet 1998;352:930-942. Abstract
Early Breast Cancer Trialists’ Collaborative Group. Systemic
treatment of early breast cancer by hormonal, cytotoxic, or immune
therapy: 133 randomised trials involving 31,000 recurrences and
24,000 deaths among 75,000 women. Lancet 1992;339:1-15
& 71-85. Abstract
Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen
for early breast cancer: An overview of the randomised trials.
Lancet 1998;351:1451-1467. Abstract
Favourable and unfavourable effects on long-term survival of radiotherapy
for early breast cancer: An overview of the randomised trials. Early
Breast Cancer Trialists’ Collaborative Group. Lancet
2000;355(9217):1757-70. Abstract
TAC vs FAC in the adjuvant and metastatic setting
Mackey JR et al. Final results of the phase III randomized
trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide
(C) to FAC as first-line chemotherapy (CT) for patients (pts) with
metastatic breast cancer (MBC). Proc ASCO 2002;Abstract
137.
Nabholtz JM et al. Phase II study of docetaxel, doxorubicin,
and cyclophosphamide as first-line chemotherapy for metastatic breast
cancer. J Clin Oncol 2001;19(2):314-21. Abstract
Nabholtz JM et al. Phase III trial comparing TAC (docetaxel,
doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin,
cyclophosphamide) in the adjuvant treatment of node-positive breast
cancer (BC) patients: Interim analysis of the BCIRG 001 study.
Proc ASCO 2002;Abstract
141.
|
